A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

NCT00683475 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: IMC-A12
DRUG: Mitoxantrone
DRUG: Prednisone
BIOLOGICAL: IMC-1121B (ramucirumab)

Sponsor

Eli Lilly and Company